| Molecule | Cat. No. | Product Name | Art | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| HLA-G & B2M & Peptide (RIIPRHLQL) | Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein (MALS verified) | Human | HEK293 | MALSSDS-PAGE | $335.00 25ug | ||||
| HLA-G & B2M & Peptide (RIIPRHLQL) | Biotinylated Human HLA-G&B2M&Peptide (RIIPRHLQL) Complex Protein (Monomer, MALS verified) | Human | HEK293 | MALSSDS-PAGE | $125.00 25ug |
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Osugacestat | AL-101(BMS); BMS-906024 | Phase 2 Clinical | Bristol-Myers Squibb Company, Glaxosmithkline Plc | Triple Negative Breast Neoplasms; Neoplasms; Carcinoma, Adenoid Cystic; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |